Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good luck yooper. Hope things improve for us all.
Agree. I personally speaking for myself think it's way to late to sell now. I have no doubt we will move up but to where is the question. It was tough just to get to .50 cents and now there's millions below .15. Holding for a dollar seems out of reach even with the start of phase3 unless Leo gets us a deal with meat on the bone. I will reassess at .30cents hopefully. I've even added down here thinking things will improve. We'll see.
There's B-OM(oral mucositis)and there's Ulcerative Colitis, ulcerative proctitis/proctosigmoiditis. All heavy hitters for a non-biologic. With B there are many possibilities but I suspect at this point we need BP expertise.
It's a quite a large market of need.
The NIH could use B against Dengue fever and Malaria. Chikungunya is also tropical virus NIH could target. There is a plethora of other tropical diseases.
"NIH scientists and academic researchers, and may introduce opportunities to study Brilacidin in neglected tropical diseases".
B could likely provide multiple avenues to revenue but in my opinion we need some BP expertise to get us there.
Last pr- "More broadly, evaluation of Brilacidin’s broad-spectrum antiviral properties continues through collaborations with NIH scientists and academic researchers, and may introduce opportunities to study Brilacidin in neglected tropical diseases. The Company plans to announce new findings as they are reported to us"
Skin conditions is huge market.
Yep some good news on the deeper analysis would certainly be welcomed.
https://www.nih.gov/news-events/nih-research-matters/fecal-transplants-restore-gut-microbes-after-antibiotics
Something they've successfully done to restore gut health.
Maybe higher dosing gives evidence that the trial dosing was just too low which caused B not to meet its primary endpoint. If so what a screw up. Just have to wait and see. Hoping further data meets the government anti-viral testing program.
Compassionate use patients blood tests should confer whether higher doses better clear the virus.
The antiviral virucidal blocking properties of B would be a huge market if also implemented against yearly cold and viruses. Would like to see more on this effort.
"Initial feasibility work to formulate Brilacidin for potential prophylactic use via inhaled delivery, to leverage Brilacidin’s unique virucidal and blocking antiviral properties, also is underway."
Yes we have actual clinical trials that proves B works on multiple diseases. Lots of money spent in UC treatments. I would think partnering on a non-biologic UC pill would be quite enticing for any BP in this space. I think Leo needs to go back to Locust Walk and market B as a likely UC treatment. OM is not necessarily a BP thing but more for smaller pharmas. The value is in the whole package. We'll see.
Yes true. Hospitalized patients would have been more severe cases. Thanks.
They had to be hospitalized patients, mild cases are not hospitalized. This likely went into trial design.
They put B against standard of care Remdesiver so there was a mild option. I wish we would have been in a mild arm.
Mild cases have good options I would surmise that dictated our trial plan. Hopefully we strike some gold here-
"Brilacidin has been shipped to two academic laboratories for planned in vitro testing of Brilacidin in over 20 acutely infectious viruses, including Ebola, Marburg, Nipah, West Nile and Zika, through a collaboration with U.S. government scientists. The goal of this testing is to further inform the spectrum of Brilacidin's antiviral properties".
That's what I'm waiting to see. Thanks.
Polymedix went to 80 bucks I wish we had that problem.
B has a lot to offer so I figure there's relevant news coming that will pull us out of the stinky mud so I added also.
Positive results here may get us government support.
"The Company is also pleased to report Brilacidin has been shipped to two academic laboratories for planned in vitro testing of Brilacidin in over 20 acutely infectious viruses, including Ebola, Marburg, Nipah, West Nile and Zika, through a collaboration with U.S. government scientists. The goal of this testing is to further inform the spectrum of Brilacidin's antiviral properties".
That's how I read it. We were in a tough patient population so I would think if B is shown to lessen the viral load that would be a very important secondary analysis.
Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin’s Potential Inclusion in Government-Sponsored COVID-19 Trials
Thanks for posting. Agree with covid waning AS will soon get trial running.
Brilacidin exerts antiviral activity prior to infection of cells,
Agree OM would likely be next. The company chart shows the arrow piercing into phase3 (for what ever that's worth). Hopefully those packets are ready. Perhaps better news will come out of covid.
Thanks casher. Yes B's actual anti-viral ability in the blood stream is needed information.
Covid-19 testing has shown Brilacidin to have anti-viral activity against many multiple virus types. Have to wait see what happens with that effort. My hope is we see some government money.
I say lets get on to recruiting phase3 OM. Covid has waned considerably.
Yep we found that out. Fortunately B shows promise in treating OM.
What about the B-rinse/mouthwash for reducing oral mucositis for chemo/radiation for treatment of head and neck cancer?
That seemed promising - especially for chemo patients. Unless I'm missing something? And iirc, there's something >60K cases of head and neck cancer each year in the USA alone, and this study had patients use it for 7weeks. This seems doable - but again, I'm a noob with IPIX, and this area of research.
What am I missing?
Certainly proven as a antibiotic (ABSSSI) and anti-inflammatory (UP/UPRS). My opinion antiviral anti-inflammatory property's will have further investigation. Hopefully things get back on track soon. I figure everyone here has an interest one way or another.
Alzheimer's drug cited as Medicare premium jumps by $21.60
"Medicare officials told reporters on Friday that about half the increase is due to contingency planning if the program ultimately has to cover Aduhelm, the new $56,000-a-year medication for Alzheimer's disease from pharmaceutical company Biogen. The medication would add to the cost of outpatient coverage because it's administered intravenously in a doctor's office and paid for under Part B."
https://www.yahoo.com/news/alzheimers-drug-cited-medicare-premium-220744908.html
Oral Blarcamesine to the rescue!
I say yes way over sold but the market speaks, Leo reported initiating a phase3 OM in early 2022. B in a nebulizer study could be warranted? what else might be? Covid gave us new insights but we are now 2 years behind imo
I too must have gagged 20 or so.lol
Picked up 70000 below .09 this morning. We've been here before. Ok back to 30cents.
You must have grabbed on to some tail feathers..
To Flip say it isn't so.
.098 is where mm's have it parked for now.
edit-I see it's pushing into .dime.
These approved FDA treatment methods that B uses for delivery could change patenting. It happens all the time. When FDA approves drugs there's a chance for 3-5 years added market exclusivity.
Great thought, B as a nebulizer may open a wider range of possibilities in just treating lung disease. Thanks.